EE286 Post-Infusion Monitoring Costs By Site of Care Among Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) Who Received Second-LINE Treatment with Lisocabtagene Maraleucel (LISO-CEL) in the Transform Study: A United States Subgroup Analysis

Abstract

Although chimeric antigen receptor T cell therapy is generally administered in the inpatient setting, opportunities exist for treatment in the outpatient setting to reduce costs. Post-infusion costs for liso-cel by site of care may differ between the United States (US) and other countries. This analysis assessed post-infusion monitoring costs by site of care among US patients with LBCL treated with liso-cel as a second-line therapy in the TRANSFORM study (NCT03575351).